Prevalence and antimicrobial susceptibility of Pseudomonas aeruginosa mucoid and non-mucoid type

Southeast Asian Journal of Tropical Medicine and Public Health

Volumn 35, Issue 4, 2004, Pages 893-896

  Srifuengfung, Somporn ^a   Tiensasitorn, Chuntima ^a   Yungyuen, Thitiya ^a   Dhiraputra, Chertsak ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFPIROME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; MEROPENEM; NETILMICIN; OFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; SULPERAZON; SULTAMICILLIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CONTROLLED STUDY; DIFFUSION; DRUG CHOICE; HUMAN; PHENOTYPE; PRACTICE GUIDELINE; PREVALENCE; PSEUDOMONAS AERUGINOSA;

EID: 12444320761     PISSN: 01251562     EISSN: 26975718     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Ahangarzadeh-Rezaee M, Behzadiyan-Nejad Q, Najjar-Pirayeh S. Higher aminoglycoside resistance in mucoid Pseudomonas aeruginosa than in non-mucoid strains. Arch Iranian Med 2002; 5: 251-54.
2. Bonfiglio C, Carciotto V, Russo G, et al. Antibiotic resistance in Pseudomonas aeruginosa, an Italian surveys. J Antimicrob Chemother 1998; 41: 307-10.
3. Camell Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999; 43: 1379-82.
4. Ciofu O, Fussing V, Bagge N, Koch C, Hoiby N. Characterization of paired mucoid/non-mucoid Pseudomonas aeruginosa isolates from Danish cystic fibrosis patients: antibiotic resistance, β-lactamase acitivity and riboprinting. J Antimicrob Chemother 2001; 48: 391-6.
5. Eldere JV. Multicenter surveillance of Pseudomonas aeruginosa susceptibility pattern in nosocomial infections. J Antimicrob Chemother 2003; 51: 347-52.
6. Goven JR, Harris GS. Pseudomonas aeruginosa and cystic fibrosis: unusual bacterial adaptation and pathogenesis. Microbiol Sci 1986; 3: 302-8.
7. Mathee K, Ciofu O, Sternberg C, et al. Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the crystic fibrosis lung. Microbiol 1999; 145: 1349-57.
8. thed. Washington DC: American Society for Microbiology, 1999: 283-96.
9. th ed. Villanova, Pa: NCCLS, 2002.
10. Ogle JW, Janda JM, Woods DM, Vasil ML. Characterization and use of a DNA probe as an epidemiological marker for Pseudomonas aeruginosa. J Infect Dis 1987; 155: 119-26.
11. Schulin T. In vitro activity of the aerosolized agents colitin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in Southwestern Germany. J Antimicrob Chemother 2002;49:403-6.
12. Shawar RM, Macleod DL, Garber RL, et al. Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 1999; 43: 2877-80.